2509 Stock Overview
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on biologic therapies for autoimmune and allergic diseases in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Qyuns Therapeutics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$25.60 |
| 52 Week High | HK$28.20 |
| 52 Week Low | HK$18.14 |
| Beta | 0 |
| 1 Month Change | 13.78% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 4.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2509 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 3.2% | 8.1% | 2.8% |
| 1Y | n/a | -34.2% | -8.1% |
Return vs Industry: Insufficient data to determine how 2509 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2509 performed against the Hong Kong Market.
Price Volatility
| 2509 volatility | |
|---|---|
| 2509 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2509's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2509's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 323 | Jiwan Qiu | www.qyuns.net |
Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on biologic therapies for autoimmune and allergic diseases in the People’s Republic of China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor for the treatment of ankylosing spondylitis (AS) and lupus nephritis (LN); and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra to treat atopic dermatitis (AD), prurigo nodularis (PN), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU), asthma, and chronic obstructive pulmonary disease (COPD). The company also develops QX001S, an IL-12/IL-23p40 inhibitor for the treatment of psoriasis (Ps) and ulcerative colitis (UC)/Crohn’s disease (CD); QX004N an IL-23p19 inhibitor to treat Ps and CD; QX006N, an IFNAR1-targeting mAb for the treatment of systemic lupus erythematosus (SLE); and QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin designed to treat moderate-to-severe asthma and COPD.
Qyuns Therapeutics Co., Ltd. Fundamentals Summary
| 2509 fundamental statistics | |
|---|---|
| Market cap | HK$4.89b |
| Earnings (TTM) | -HK$513.33m |
| Revenue (TTM) | HK$13.65m |
384.1x
P/S Ratio-10.2x
P/E RatioIs 2509 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2509 income statement (TTM) | |
|---|---|
| Revenue | CN¥12.64m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥12.64m |
| Other Expenses | CN¥488.16m |
| Earnings | -CN¥475.52m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.32 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,761.43% |
| Debt/Equity Ratio | 79.5% |
How did 2509 perform over the long term?
See historical performance and comparison